Abstract
Ever since the discovery of estradiol and the elucidation of its chemical structure, there has been a great deal of interest in its mechanism of action and its potential therapeutic value. It is now well established that estrogens have many different functions in many different cell-types. With respect to the potential use of estrogens as therapeutics, there is an interest in controlling reproductive function, bone metabolism, cardiovascular disease, as well as in the prevention of hot flushes, mood changes and Alzheimers disease. For over a decade, it was believed that estrogens signal through a a single estrogen receptor, now referred to as ER alpha, which belongs to a family of ligand-activated transcription factors. More recently, however, a second estrogen receptor ERb was identified. The current review describes similarities as well as differences between these two distinct estrogen receptors. Both ER alpha and ER beeta bind 17beeta-estradiol with high affinity and they bind to classical estrogen response elements in a similar if not identical fashion. However, there are also major differences between ER alpha and ERbeeta for instance with respect to their tissue distribution, the phenotype of the corresponding knock-out mice and their transcriptional activities. It is anticipated that a better understanding of these two receptors will eventually lead to more selective ways of modulating physiological processes which are influenced by estrogens. For this purpose, the development of ERa and ERb specific ligands, both agonists as well as antagonists, will be of great importance.
Keywords: estrogen receptor, nuclear receptor gene, glucocorticoid GR, DNA binding domain DBD, MAPK mediated serine phosphorylation, agonists antagonsits, anti estrogen 4 hydroxytamoxifen OHT, Splice variants, transcriptional co regualtors, ligand independent activation, hormone replacement therapy, ligand binding specificity, high throughput screening assays
Current Medicinal Chemistry
Title: Estrogen Receptors alpha and beeta Two Receptors of a Kind
Volume: 7 Issue: 5
Author(s): Koen Dechering, Christine Boersma and Sietse Mosselman
Affiliation:
Keywords: estrogen receptor, nuclear receptor gene, glucocorticoid GR, DNA binding domain DBD, MAPK mediated serine phosphorylation, agonists antagonsits, anti estrogen 4 hydroxytamoxifen OHT, Splice variants, transcriptional co regualtors, ligand independent activation, hormone replacement therapy, ligand binding specificity, high throughput screening assays
Abstract: Ever since the discovery of estradiol and the elucidation of its chemical structure, there has been a great deal of interest in its mechanism of action and its potential therapeutic value. It is now well established that estrogens have many different functions in many different cell-types. With respect to the potential use of estrogens as therapeutics, there is an interest in controlling reproductive function, bone metabolism, cardiovascular disease, as well as in the prevention of hot flushes, mood changes and Alzheimers disease. For over a decade, it was believed that estrogens signal through a a single estrogen receptor, now referred to as ER alpha, which belongs to a family of ligand-activated transcription factors. More recently, however, a second estrogen receptor ERb was identified. The current review describes similarities as well as differences between these two distinct estrogen receptors. Both ER alpha and ER beeta bind 17beeta-estradiol with high affinity and they bind to classical estrogen response elements in a similar if not identical fashion. However, there are also major differences between ER alpha and ERbeeta for instance with respect to their tissue distribution, the phenotype of the corresponding knock-out mice and their transcriptional activities. It is anticipated that a better understanding of these two receptors will eventually lead to more selective ways of modulating physiological processes which are influenced by estrogens. For this purpose, the development of ERa and ERb specific ligands, both agonists as well as antagonists, will be of great importance.
Export Options
About this article
Cite this article as:
Dechering Koen, Boersma Christine and Mosselman Sietse, Estrogen Receptors alpha and beeta Two Receptors of a Kind, Current Medicinal Chemistry 2000; 7 (5) . https://dx.doi.org/10.2174/0929867003375010
DOI https://dx.doi.org/10.2174/0929867003375010 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Recent Updates on Molecular Genetic Engineering Approaches and Applications of Human Therapeutic Proteins
Current Protein & Peptide Science L-Arginine Availability as a Pathological Mechanism in Essential Hypertension, Chronic Renal and Heart Failure
Vascular Disease Prevention (Discontinued) Radiolabeled Compounds in Diagnosis of Infectious and Inflammatory Disease
Current Pharmaceutical Design Use of Speech Analyses within a Mobile Application for the Assessment of Cognitive Impairment in Elderly People
Current Alzheimer Research Commentary (Research Highlights: Targeted Inhibition of miR-155 Promotes Post-Stroke Neovascularization and Functional Recovery)
CNS & Neurological Disorders - Drug Targets Older and Newer Strategies for the Pharmacological Management of Agitation in Patients with Bipolar Disorder or Schizophrenia
CNS & Neurological Disorders - Drug Targets Bacterial Recognition and Induced Cell Activation in Sepsis
Endocrine, Metabolic & Immune Disorders - Drug Targets Stable Angina Pectoris: Current Medical Treatment
Current Pharmaceutical Design An Overview on Natural Cholinesterase Inhibitors - A Multi-Targeted Drug Class - and Their Mass Production
Mini-Reviews in Medicinal Chemistry Carbonic Anhydrase Activation and the Drug Design
Current Pharmaceutical Design Sympathetic Nervous System, Genes and Human Essential Hypertension
Current Neurovascular Research Endogenous Facilitation: From Molecular Mechanisms to Persistent Pain
Current Neurovascular Research Female Sexual Dysfunction: Therapeutic Options and Experimental Challenges
Cardiovascular & Hematological Agents in Medicinal Chemistry Antidepressants: Update on Benefits and Risks
Current Psychopharmacology On the Horizon: Promising Investigational Antiretroviral Agents
Current Pharmaceutical Design Integrating Virtual Screening and Combinatorial Chemistry for Accelerated Drug Discovery
Combinatorial Chemistry & High Throughput Screening Editorial: (Thematic Issue: Vascular Pathophysiology of Alzheimer`s Disease)
Current Alzheimer Research Migraine and Coronary Artery Disease: An Open Study on the Genetic Polymorphism of the 5, 10 Methylenetetrahydrofolate (MTHFR) and Angiotensin I-Converting Enzyme (ACE) Genes
Central Nervous System Agents in Medicinal Chemistry Targeting Serotonin1A Receptors for Treating Chronic Pain and Depression
Current Neuropharmacology Bacteriocins Active Against Multi-Resistant Gram Negative Bacteria Implicated in Nosocomial Infections
Infectious Disorders - Drug Targets